IDIX will present IDX899 phase-1/2 monotherapy data from all dosing cohorts at: ESCMID – Mechanisms of Antimicrobial Resistance June 15-21, 2008 Palma de Mallorca, Spain <a href="http://www.escmid.org" target="_blank">http://www.escmid.org</a> Top-line data from the 800mg (highest) dose were disclosed in a PR on 2/6/08.